PPARA and metabolic dysfunction-associated steatotic liver disease: And they revealed a NO-AMPK-PPAR-α-signaling pathway that is crucial for the control of hepatic fatty acid oxidation, which might offer new drug targets for clinical treatments of NAFLD.